Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16840158 | 1.00 | TSHR (0.35) | TSHRSMN1; SMN2ELANEALOX15CA12 | |
| SCHEMBL16840157 | 1.00 | TSHR (0.35) | TSHRSMN1; SMN2ELANEALOX15CA12 | |
| SCHEMBL14420243 | 0.83 | SLC7A5 (0.36) | TSHRSMN1; SMN2 | |
| SCHEMBL18068907 | 0.83 | SLC7A5 (0.36) | TSHRSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL28011474 | 0.81 | SLC7A5 (0.35) | TSHRSMN1; SMN2 | |
| SCHEMBL21887322 | 0.81 | — | — | |
| SCHEMBL2989928 | 0.80 | TSHR (0.33) | TSHRELANE | |
| SCHEMBL26739676 | 0.80 | TP53 (0.38) | TSHRSMN1; SMN2 | |
| SCHEMBL2989930 | 0.80 | TSHR (0.33) | TSHRELANE | |
| SCHEMBL13704771 | 0.78 | TSHR (0.32) | TSHRELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357207-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | BCP3 PTY LIMITED (AU) | 2023-11-09 | — | — | US | disclosed |
| US-20230150941-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2023-05-18 | — | — | US | disclosed |
| US-20230141981-A1 | NOVEL COMPOUNDS AND COMPOSITION FOR TARGETED THERAPY OF KIDNEY-ASSOCIATED CANCERS | Shanghai MICURX Pharmaceuticals Co., Ltd. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-11639353-B2 | Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-02 | — | — | US | disclosed |
| US-11340528-B2 | Production method of composition for resist top coat layer, method of forming resist pattern, production method of fluorine-containing resin, and method of improving water repellency of resist top coat layer | JSR CORPORATION (JP) | 2022-05-24 | — | — | US | disclosed |
| US-11198673-B2 | Therapeutic compounds and compositions | EXITHERA PHARMACEUTICALS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-20210181630-A1 | PRODUCTION METHOD OF COMPOSITION FOR RESIST TOP COAT LAYER, METHOD OF FORMING RESIST PATTERN, PRODUCTION METHOD OF FLUORINE-CONTAINING RESIN, AND METHOD OF IMPROVING WATER REPELLENCY OF RESIST TOP COAT LAYER | JSR CORPORATION (JP) | 2021-06-17 | — | — | US | disclosed |
| CN-112334568-A | Isobutyrate compounds having propionyloxy group at alpha position, fragrance compositions and use as fragrance | 三菱瓦斯化学株式会社 | 2021-02-05 | — | — | CN | disclosed |
| US-10040787-B2 | Prodrugs of NH-acidic compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2018-08-07 | — | — | US | disclosed |
| US-10023537-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | ALKERMES PHARMA IRELAND LIMITED (IE) | 2018-07-17 | — | — | US | disclosed |
| US-20100112037-A1 | S1P RECEPTOR AGONISTS FOR THE TREATMENT OF CEREBRAL MALARIA | LEXICON PHARMACEUTICALS, INC. | 2010-05-06 | — | — | US | disclosed |
| US-20100016260-A1 | AGONISTS OF SPHINGOSINE-1 PHOSPHATE RECEPTOR (SLP) | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100009936-A1 | CHEMICAL COMPOUNDS | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2010-01-14 | — | — | US | disclosed |
| US-20090318389-A1 | AGONISTS OF THE SPHINGOSINE-1 PHOSPHATE RECEPTOR | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2009-12-24 | — | — | US | disclosed |
| US-20080096938-A1 | Immunosuppressants for autoimmune diseases such as multiple sclerosis, transplant rejection; sphingosine-1-phosphate (S1P) receptor agonists; (S)-2-Amino-2-(5-(4-(2-(pentyloxy)ethoxy)-3-(trifluoromethyl)phenyl)-1,3,4-thiadiazol-2-yl)propyl dihydrogen phosphate for example | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-04-24 | — | — | US | disclosed |
| US-20080096938-A1 | Immunosuppressants for autoimmune diseases such as multiple sclerosis, transplant rejection; sphingosine-1-phosphate (S1P) receptor agonists; (S)-2-Amino-2-(5-(4-(2-(pentyloxy)ethoxy)-3-(trifluoromethyl)phenyl)-1,3,4-thiadiazol-2-yl)propyl dihydrogen phosphate for example | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-04-24 | — | — | US | disclosed |
| US-20080070866-A1 | Chemical compounds | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-03-20 | — | — | US | disclosed |
| US-20080064662-A1 | Methods and compositions for modulating sphingosine -1- phosphate (S1P) receptor activity | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-03-13 | — | — | US | disclosed |
| US-7241812-B2 | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241812-B2 | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064662-A1 | Methods and compositions for modulating sphingosine -1- phosphate (S1P) receptor activity | S1PR1, S1PR2, S1PR3 | TSHR 642/4885SMN1; SMN2 1924/4885ELANE 2291/4885 |
| US-10023537-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | GABBR1, GABBR2, GABRE | TSHR 1280/4885SMN1; SMN2 673/4885ELANE 4084/4885 |
| US-10040787-B2 | Prodrugs of NH-acidic compounds | SI, NAAA, NIT2 | TSHR 3738/4885SMN1; SMN2 606/4885ELANE 130/4885 |
| US-20100112037-A1 | S1P RECEPTOR AGONISTS FOR THE TREATMENT OF CEREBRAL MALARIA | S1PR1, S1PR2, S1PR3 | TSHR 839/4885SMN1; SMN2 2350/4885ELANE 1582/4885 |
| US-11198673-B2 | Therapeutic compounds and compositions | KLK5, KLKB1, KLK2 | TSHR 4208/4885SMN1; SMN2 4040/4885ELANE 57/4885 |
| US-11639353-B2 | Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | ITGB1, ITGB2, ITGA1 | TSHR 1934/4885SMN1; SMN2 2790/4885ELANE 1720/4885 |
| US-20230150941-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | GABBR1, GABBR2, GABRE | TSHR 1280/4885SMN1; SMN2 673/4885ELANE 4084/4885 |
| US-20100016260-A1 | AGONISTS OF SPHINGOSINE-1 PHOSPHATE RECEPTOR (SLP) | S1PR1, S1PR2, S1PR5 | TSHR 153/4885SMN1; SMN2 1302/4885ELANE 2707/4885 |
| US-20090318389-A1 | AGONISTS OF THE SPHINGOSINE-1 PHOSPHATE RECEPTOR | S1PR1, S1PR3, S1PR5 | TSHR 138/4885SMN1; SMN2 1622/4885ELANE 3051/4885 |
| US-20080096938-A1 | Immunosuppressants for autoimmune diseases such as multiple sclerosis, transplant rejection; sphingosine-1-phosphate (S1P) receptor agonists; (S)-2-Amino-2-(5-(4-(2-(pentyloxy)ethoxy)-3-(trifluoromethyl)phenyl)-1,3,4-thiadiazol-2-yl)propyl dihydrogen phosphate for example | S1PR1, S1PR2, S1PR5 | TSHR 242/4885SMN1; SMN2 2847/4885ELANE 3657/4885 |
| US-20080070866-A1 | Chemical compounds | S1PR1, S1PR2, S1PR5 | TSHR 818/4885SMN1; SMN2 4481/4885ELANE 2099/4885 |
| US-20230357207-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | MUC1, MPO, SERPINB1 | TSHR 1561/4885SMN1; SMN2 4712/4885ELANE 6/4885 |
| US-20230141981-A1 | NOVEL COMPOUNDS AND COMPOSITION FOR TARGETED THERAPY OF KIDNEY-ASSOCIATED CANCERS | GLS, ATP6V1B1, KRAS | TSHR 4421/4885SMN1; SMN2 4686/4885ELANE 2822/4885 |
| US-20100009936-A1 | CHEMICAL COMPOUNDS | CD4, ICOS, NFATC1 | TSHR 228/4885SMN1; SMN2 3973/4885ELANE 934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.